Brief: Celyad Oncology Presents Data Update From Phase 1 alloSHRINK Trial For CYAD-101 In mCRC
18/01/2021 06:13
Jan 18 (Reuters) - Celyad Oncology CYAD.BR :
* CELYAD ONCOLOGY PRESENTS DATA UPDATE FROM PHASE 1
ALLOSHRINK
TRIAL FOR CYAD-101 IN MCRC AT ASCO-GI SYMPOSIUM
* MEDIAN OVERALL SURVIVAL AND MEDIAN PROGRESSION FREE
SURVIVAL
FROM DOSE-ESCALATION SEGMENT OF TRIAL WERE 10.6 MONTHS AND 3.9
MONTHS, RESPECTIVELY
* TUMOR BURDEN DECREASE OBSERVED IN EIGHT OF 15 REFRACTORY
UNRESECTABLE MCRC PATIENTS, INCLUDING SIX OF NINE PATIENTS AT
HIGHEST DOSE LEVEL OF 1X10(9) CELLS PER INFUSION
* PRELIMINARY DATA FROM ONGOING EXPANSION COHORT OF PHASE 1
ALLOSHRINK EXPECTED IN FIRST HALF OF 2021
Source text for Eikon: ID:nGNX6wpf2C
Further company coverage: CYAD.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))